Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Top Cited Papers
- 9 January 2012
- journal article
- review article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 24 (2), 207-212
- https://doi.org/10.1016/j.coi.2011.12.009
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- The PDL1-PD1 Axis Converts Human T H 1 Cells into Regulatory T CellsScience Translational Medicine, 2011
- PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in miceThe Journal of Experimental Medicine, 2011
- Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaquesJournal of Clinical Investigation, 2010
- Tumor-infiltrating NY-ESO-1–specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancerProceedings of the National Academy of Sciences, 2010
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cellsThe Journal of Experimental Medicine, 2009
- Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+The Prostate, 2009
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodiesThe Journal of Experimental Medicine, 2009
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infectionNature Immunology, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007